ONKURE THERAPEUTICS, INC. Expense Breakdown
No Expense Breakdown for OKUR on this site yet.
- 2026-06-30: Clinical Research $3.05M.
- 2025-06-30: Clinical Research $2.91M.
Source checked: the stored Expense Breakdown page for OKUR.
Expenses by product
Share-based Payment Arrangement, Expense: each quarter (3 month)
| Quarter end | Clinical Research |
|---|---|
| 2026-06-30 | $3.05M |
| 2025-06-30 | $2.91M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |